Annual General Meeting

Investor Contact Sylke Maas, Ph.D.
VP Investor Relations & Strategy
Send Email
+49 6131 9084-0
For U.S. Investors:
Westwicke
John Woolford
Send Email
+1 443 213-0506
Media Contact Jasmina Alatovic
Director Global External Communications
Send Email
+49 6131 9084-0

Annual General Meeting 2021

The Annual General Meeting 2021 of BioNTech SE was held on June 22, 2021 as a virtual Annual General Meeting without the physical presence of shareholders or their proxies.

AGM Voting Results 2021

AGM Voting Results

 

Presentations and Speeches

Speech of Prof. Dr. Ugur Sahin (CEO)

Speech of Dr. Sierk Poetting (COO/CFO)

AGM Presentation CEO and COO/CFO

 

 

 

INFORMATION AND DOCUMENTS FOR THE VIRTUAL ANNUAL GENERAL MEETING

Invitation to the Annual General Meeting 2021

Table pursuant to Sec. 125 Stock Corporation Act in conjunction with EU Regulation 2018/1212

 

Documents on Agenda Items 1 and 13

BioNTech Annual Report 2020 (German)

BioNTech SE Annual Financial Statements 2020

BioNTech SE Consolidated Financial Statements 2020

BioNTech SE Combined Management Report 2020

Report of the Supervisory Board on the 2020 Financial Year

Sustainability Report 2020

 

Explanation to Agenda Item 1

Explanation to Agenda Item 1 Sec. 124a Sentence 1 No. 2 Stock Corporation Act

 

Documents on Agenda Items 5, 8 and 9

Report of the Management Board on the Resolution on the Revocation of the Existing Authorized Capital and the Implementation of a New Authorized Capital and
Report of the Management Board on the Amendment of the Existing Authorization to Acquire Treasury Shares and
Report of the Management Board on the Extension of the Authorization to Acquire Treasury Shares

 

Documents on Agenda items 5, 7 and 11

BioNTech SE Articles of Association

 

Documents on agenda item 13

JPT Peptide Technologies GmbH

Domination and Profit and Loss Transfer Agreement between BioNTech SE and JPT Peptide Technologies GmbH

Joint Report pursuant to Sec. 293 Stock Corporation Act of BioNTech SE and JPT Peptide Technologies GmbH for the Domination and Profit and Loss Transfer Agreement

Report on the Audit of the Domination and Profit and Loss Transfer Agreement between BioNTech SE and JPT Peptide Technologies GmbH

 

JPT Peptide Technologies GmbH Closing Balance Sheet and Profit and Loss 2018-2020 

JPT Peptide Technologies GmbH Closing Balance Sheet and Profit and Loss 2018

JPT Peptide Technologies GmbH Closing Balance Sheet and Profit and Loss 2019

JPT Peptide Technologies GmbH Closing Balance Sheet and Profit and Loss 2020

 

BioNTech Manufacturing Marburg GmbH

Domination and Profit and Loss Transfer Agreement between BioNTech SE and BioNTech Manufacturing Marburg GmbH (previously Novartis Manufacturing GmbH)

Joint Report pursuant to Sec. 293 Stock Corporation Act of BioNTech SE and BioNTech Manufacturing Marburg GmbH for the Domination and Profit and Loss Transfer Agreement

 

BioNTech Manufacturing Marburg GmbH Closing Balance Sheet and Profit and Loss 2018-2020 

BioNTech Manufacturing Marburg GmbH Closing Balance Sheet and Profit and Loss 2018

BioNTech Manufacturing Marburg GmbH Closing Balance Sheet and Profit and Loss 2019

BioNTech Manufacturing Marburg GmbH Closing Balance Sheet and Profit and Loss 2020
 

 

reSano GmbH

Domination and Profit and Loss Transfer Agreement between BioNTech SE and reSano GmbH

Joint Report pursuant to Sec. 293 Stock Corporation Act of BioNTech SE and reSano GmbH for the Domination and Profit and Loss Transfer Agreement reSano GmbH Closing Balance

 

reSano GmbH Closing Balance Sheet and Profit and Loss 2018-2020 
 

RO closing balance sheet; Profit and Loss 2018

RO closing balance sheet; Profit and Loss 2019

RO closing balance sheet; Profit and Loss 2020

 

Further Documents and Forms

Explanation of Shareholder Rights

Registration, Voting and Proxy Form

Notes on Data Protection

 

Total Number of Shares and Voting Rights

Total Number of Shares and Voting Rights

 

Countermotions and Election Proposals

There are currently no countermotions and election proposals from shareholders.